Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
Provided By GlobeNewswire
Last update: Nov 3, 2025
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population
Encouraging safety and tolerability profile at all doses evaluated
Read more at globenewswire.com
